

## Special Issue

# Therapeutic Radionuclides in Nuclear Medicine

### Message from the Guest Editors

Sodium iodide is the first example of a theranostic radiopharmaceutical. Recently, the theranostic principle has been used with tumor receptor-specific radiopharmaceuticals containing therapeutic nuclides, such as  $^{161}\text{Tb}$ ,  $^{177}\text{Lu}$ ,  $^{188}\text{Re}$ ,  $^{212}\text{Pb}$ ,  $^{225}\text{Ac}$ . The production mode, availability, and costs of radionuclides have a significant impact on their clinical use and is often a bottleneck for broad application. Therefore, cyclotron-produced neutrons could open a new era for producing relevant radionuclides. Combining radiotherapeutics with the body's immune system or immunotherapeutics raises hopes for immunization against cancer and could explain the success of targeted alpha therapy vs. targeted beta therapy. The value of diverse radiation qualities including options such as photodynamic therapy using Cherenkov light must be systematically investigated in vitro and in preclinical models before they can be used in clinical trials and patient care. The path from radioisotope to targeted radionuclide therapy encompasses a multitude of aspects like availability, costs, dosimetry, waste management, which will be highlighted in this issue.

### Guest Editors

Dr. Marc Pretze

1 Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany  
2 Molecular Imaging and Radiochemistry, Department of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany

Prof. Dr. Jörg Kotzerke

1 Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany  
2 Helmholtz-Zentrum Dresden-Rossendorf, PET Center, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany

### Deadline for manuscript submissions

closed (31 January 2024)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/164230](https://mdpi.com/si/164230)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)